Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy

SIMPLE SUMMARY: CAR T-cell therapies represent a major advance in the treatment of relapsed B-cell non-Hodgkin lymphomas. Nevertheless, a significant proportion of these patients will experience disease progression following CAR T treatment. For these patients, no standard therapeutic procedure is e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rentsch, Vera, Seipel, Katja, Banz, Yara, Wiedemann, Gertrud, Porret, Naomi, Bacher, Ulrike, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139991/
https://www.ncbi.nlm.nih.gov/pubmed/35626120
http://dx.doi.org/10.3390/cancers14102516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139991/
https://www.ncbi.nlm.nih.gov/pubmed/35626120
http://dx.doi.org/10.3390/cancers14102516

Ejemplares similares